Francesco Amorelli

Dr. Francesco Amorelli

Radiation Oncology, Hospital Del Mar, Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AOAbrahams Ocanto
Abrahams Ocanto
MTMacarena Teja
Macarena Teja
Francesco AmorelliFrancesco Amorelli
Francesco Amorelli
FCFelipe Counago
Felipe Counago
Ariel Matias Gomez PalaciosAriel Matias Gomez Palacios
Ariel Matias Gomez Palacios
RCRamón Cantero
Ramón Cantero
Colorectal cancer (CRC) is a neoplasm with a high prevalence worldwide, with a multimodal treatment that includes a combination of chemotherapy, radiotherapy, and surgery in locally advanced stages with acceptable pathological complete response (pCR) rates, this has improved with the introduction of total neoadjuvant therapy (TNT) reaching pCR rates up to 37% in compare with classic neoadjuvant treatment (NAT) where pCR rates of around 20–25% are achieved. However, the patient population that benefits most from this therapy has not been determined, and there is a lack of biomarkers that can predict the course of the disease. Multiple biomarkers have been studied, ranging from hematological and molecular markers by imaging technique and combinations of them, with contradictory results that prevent their use in routine clinical practice. In this review, we evaluate the most robust prognostic biomarkers to be used in clinical practice, highlighting their advantages and disadvantages and emphasizing biomarker combinations and their predictive value.

9 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Francesco AmorelliFrancesco Amorelli
Francesco Amorelli
PFPalmira Foro
Palmira Foro
JBJuan Sebastian Blanco
Juan Sebastian Blanco
AOAbrahams Ocanto
Abrahams Ocanto
ANAugusto Natali
Augusto Natali
PPPedro Plaza
Pedro Plaza
Biochemical recurrence (BCR) occurs in 20–50% of patients with localized prostate cancer (PC) after radical prostatectomy (RP). Conventional imaging often fails to detect early local or systemic recurrences at low PSA levels. Positron emission tomography/computed tomography (PET/CT) with 18F-DCFPyL PSMA offers improved sensitivity and specificity for detecting recurrent disease. This study evaluates the diagnostic capability of 18F-DCFPyL PET/CT in early BCR of PC following RP and its impact on therapeutic decision-making and clinical management. Methods: In a prospective study, 85 patients with BCR (PSA 0.2–2.0 ng/mL) and negative conventional imaging underwent 18F-DCFPyL PET/CT. Detection rates (DRs) were analyzed against clinical variables, including PSA levels and PSA doubling time (DT-PSA). Lesions were classified into local recurrence, lymph node involvement, bone, and visceral disease. Therapeutic decisions were adjusted based on PET/CT findings. Results: 18F-DCFPyL PET/CT identified lesions in 53% of patients, with DRs of 31.3%, 60%, and 77.8% for PSA levels 1 ng/mL, respectively. DRs were significantly associated with shorter DT-PSAs (<6 months: 61.5%). The lesions detected included 22.2% local recurrences, 51.1% lymph node disease, 20% bone, and 6.7% visceral involvement. ROC analysis determined optimal PSA and DT-PSA cutoffs of 0.55 ng/mL and 9.2 months, respectively. Therapeutic strategies were modified in 84.4% of PET-positive cases. Conclusions: 18F-DCFPyL PET/CT demonstrates high sensitivity for detecting recurrent PC at low PSA levels, significantly impacting therapeutic decisions and optimizing clinical management. These findings support its integration into guidelines for managing early BCR of PC.

9 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Francesco AmorelliFrancesco Amorelli
Francesco Amorelli
PPPedro Plaza
Pedro Plaza
ANAugusto Octavio Natali
Augusto Octavio Natali
JCJuan Sebastian Blanco Cano
Juan Sebastian Blanco Cano
XDXavier Duran
Xavier Duran
PFPalmira Foro
Palmira Foro
Biochemical recurrence (BCR) after radical prostatectomy (RP) frequently occurs despite negative conventional imaging, making salvage treatment decisions challenging. We evaluated the impact of 18F-DCFPyL-PSMA PET/CT on disease detection and radiotherapy planning in patients with occult BCR. Methods: We conducted a prospective single-center observational study including 85 patients with BCR after RP, negative or inconclusive conventional imaging, and PSA levels between 0.2 and 1.0 ng/mL or persistent PSA after previous local treatment. Detection rates (DRs) were evaluated according to PSA level, PSA doubling time (PSA-DT), and International Society of Urological Pathology (ISUP) grade. Changes in radiotherapy planning and treatment intensification were assessed by comparing intended management before and after PSMA PET/CT. Results: PSMA PET/CT detected recurrent disease in 53% of patients. DRs increased significantly with PSA level, reaching 31.3% for PSA 0.2–0.5 ng/mL, 60.0% for PSA 0.5–0.9 ng/mL, and 77.8% for PSA 1.0 ng/mL (p < 0.001). Detection was also associated with shorter PSA-DT and higher ISUP grade. Pelvic lymph nodes (LNs) represented the predominant site of recurrence, accounting for 48 of 79 detected lesions. Treatment strategy changed in 97.8% of patients with positive scans, while radiotherapy planning was modified in 84.4%. PSMA PET/CT enabled expansion of target volumes, focal dose escalation, metastasis-directed stereotactic body radiotherapy (SBRT), systemic treatment intensification, and in selected patients with negative findings, treatment de-escalation to active surveillance. Following PSMA-guided treatment adaptation, the median PSA level at 24 months was 0.08 ng/mL, with early biochemical responses (BRs) observed during follow-up. Conclusions: 18F-DCFPyL-PSMA PET/CT provides clinically meaningful information beyond disease detection by substantially modifying radiotherapy planning and treatment selection in patients with occult BCR after RP. These findings support the integration of molecular imaging into salvage treatment planning to enable more personalized, biology-driven radiotherapy strategies.